Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series
Journal for ImmunoTherapy of Cancer · 2024-01 · 12 (1) · e008232
DOI: 10.1136/jitc-2023-008232 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 31.01.2024. Verfasst von Catriona Harvey und 21 weiteren Autor:innen. Beteiligte Einrichtung: Westmead Hospital WNH, Westmead, New South Wales, Australia. Hauptthemen laut MEDLINE: Colitis, Biological Products. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Immune checkpoint inhibitor (ICI) gastrointestinal toxicity (gastritis, enteritis, colitis) is a major cause of morbidity and treatment-related death. Guidelines agree steroid-refractory cases warrant infliximab, however best management of infliximab-refractory ICI gastrointestinal toxicity (IRIGItox) is unknown.
Methods
We conducted an international multicenter retrospective case series. IRIGItox was defined as failure of symptom resolution ≤grade 1 (Common Terminology Criteria for Adverse Events V.5.0) following ≥2 infliximab doses or failure of symptom resolution ≤grade 2 after one dose. Data were extracted regarding demographics, steroid use, response to treatment, and survival outcomes. Toxicity was graded at symptom onset and time of infliximab failure. Efficacy of infliximab refractory therapy was assessed by symptom resolution, time to resolution and steroid wean duration. Survival outcomes were examined based on immunosuppressive therapy received.
Results
78 patients were identified: median age 60 years; 56% men; majority melanoma (N=70, 90%); 60 (77%) received anti-cytotoxic T-lymphocyte-associated protein 4 alone or in combination with anti-programmed cell death protein-1 and most had colitis (N=74, 95%). 106 post-infliximab treatments were given: 31 calcineurin inhibitors (CNIs); 27 antimetabolites (mycophenolate, azathioprine); 16 non-systemic immunomodulatory agents (eg, mesalazine or budesonide); 15 vedolizumab; 5 other biologics (anti-interleukin-12/23, 16, Janus kinase inhibitors) and 7 interventional procedures (including colectomy); 5 did not receive post-infliximab therapy. Symptom resolution was achieved in most (N=23/31, 74%) patients treated with CNIs; 12/27 (44%) with antimetabolites; 7/16 (44%) with non-systemic immunomodulation, 8/15 (53%) with vedolizumab and 5/7 (71%) with interventional procedures. No non-vedolizumab biologics resulted in toxicity resolution. CNIs had the shortest time to symptom resolution (12 days) and steroid wean (43 days); however, were associated with poorer event-free survival (6.3 months) and overall survival (26.8 months) than other agents. Conversely, vedolizumab had the longest time to toxicity resolution and steroid wean, 66 and 124 days, but most favorable survival data: EFS 24.5 months; median OS not reached. Six death occurred (three due to IRIGItox or management of toxicity; three with persisting IRIGItox and progressive disease).
Conclusions
IRIGItox causes major morbidity and mortality. Management is heterogeneous. CNIs appear most likely to result in toxicity resolution in the shortest time period, however, are associated with poorer oncological outcomes in contrast to vedolizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Westmead Hospital WNH, Westmead, New South Wales, Australia.
- Melanoma Institute Australia, North Sydney, New South Wales, Australia.
- The University of Sydney, Sydney, New South Wales, Australia.
- Research and Biostatistics Group, Melanoma Institute Australia, North Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- Royal Marsden Hospital NHS Trust, London, UK.
ORCID-Profile: Catriona Harvey, Serigne N Lo, Bastian Schilling, Lisa Zimmer, Yinghong Wang
Zitieren
APA
Harvey, C., Nahar, K. J., McKeown, J., Lo, S. N., Farag, S., Yousaf, N., Young, K., Tas, L., Meerveld-Eggink, A., Blank, C., Thomas, A., McQuade, J., Schilling, B., Johnson, D. B., Huertas, R. M., Arance, A., Lee, J., Zimmer, L., Long, G. V., …, & Menzies, A. M. (2024). Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. Journal for ImmunoTherapy of Cancer, 12(1), e008232. https://doi.org/10.1136/jitc-2023-008232
Vancouver
Harvey C, Nahar KJ, McKeown J, Lo SN, Farag S, Yousaf N, et al. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. Journal for ImmunoTherapy of Cancer. 2024;12(1):e008232. doi:10.1136/jitc-2023-008232
BibTeX
@article{Harvey2024,
author = {Harvey, Catriona and Nahar, Kazi J and McKeown, Janet and Lo, Serigne N and Farag, Sheima and Yousaf, Nadia and Young, Kate and Tas, Liselotte and Meerveld-Eggink, Aafke and Blank, Christian and Thomas, Austin and McQuade, Jennifer and Schilling, Bastian and Johnson, Douglas B and Huertas, Roberto Martín and Arance, Ana and Lee, Joanna and Zimmer, Lisa and Long, Georgina V and Carlino, Matteo S and Wang, Yinghong and Menzies, Alexander Maxwell},
title = {Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {1},
pages = {e008232},
doi = {10.1136/jitc-2023-008232}
}
EUVIMED